JP2023549167A5 - - Google Patents

Info

Publication number
JP2023549167A5
JP2023549167A5 JP2023527966A JP2023527966A JP2023549167A5 JP 2023549167 A5 JP2023549167 A5 JP 2023549167A5 JP 2023527966 A JP2023527966 A JP 2023527966A JP 2023527966 A JP2023527966 A JP 2023527966A JP 2023549167 A5 JP2023549167 A5 JP 2023549167A5
Authority
JP
Japan
Prior art keywords
nucleic acid
mitochondrial
acid molecule
disease
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527966A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549167A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058286 external-priority patent/WO2022099034A2/en
Publication of JP2023549167A publication Critical patent/JP2023549167A/ja
Publication of JP2023549167A5 publication Critical patent/JP2023549167A5/ja
Pending legal-status Critical Current

Links

JP2023527966A 2020-11-06 2021-11-05 ミトコンドリアタンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法 Pending JP2023549167A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110625P 2020-11-06 2020-11-06
US63/110,625 2020-11-06
PCT/US2021/058286 WO2022099034A2 (en) 2020-11-06 2021-11-05 Mitochondrial protein targeting engineered deubiquitinases and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023549167A JP2023549167A (ja) 2023-11-22
JP2023549167A5 true JP2023549167A5 (cg-RX-API-DMAC7.html) 2024-11-12

Family

ID=81458643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527966A Pending JP2023549167A (ja) 2020-11-06 2021-11-05 ミトコンドリアタンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法

Country Status (7)

Country Link
US (1) US20240026330A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240753A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023549167A (cg-RX-API-DMAC7.html)
CN (1) CN116802199A (cg-RX-API-DMAC7.html)
AU (1) AU2021376278A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200982A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022099034A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115998769B (zh) * 2022-11-02 2025-12-09 中国人民解放军军事科学院军事医学研究院 以Mysm1基因为抑制靶标的物质在提高线粒体活性中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012177549A (ja) * 2009-06-24 2012-09-13 Hokkaido Univ 蛍光温度プローブおよびそれを用いた温度測定装置
EP2992892A1 (en) * 2014-09-05 2016-03-09 Universität zu Köln Fusion protein for use in the treatment of mitochondrial diseases
EP3706782A4 (en) * 2017-11-06 2021-09-08 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS OF USING MANIPULATED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELL PROCESSES
WO2019126762A2 (en) * 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
AU2020224327B2 (en) * 2019-02-21 2022-09-29 Entact Bio Limited Survival-targeting chimeric ( SURTAC) molecules

Similar Documents

Publication Publication Date Title
EP3794024B1 (en) Activatable interleukin-2 polypeptides and methods of use thereof
US20220267400A1 (en) Il-2 cytokine prodrugs comprising a cleavable linker
EP4034551A1 (en) Cytokine prodrugs and dual-prodrugs
AU2003298187B2 (en) Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2
EP2970512B1 (en) Fusion immunomodulatory proteins and methods for making same
EP1301605B1 (en) Nk cells activating receptors and their therapeutic and diagnostic uses
CN112654636A (zh) 可活化白介素12多肽及其使用方法
KR20030048041A (ko) 표적-특이적 프로드럭으로서 사용하기 위한항체-사이토카인-사이토카인 억제제로 이루어진 융합단백질(셀렉토카인)
WO2017025698A1 (en) Bispecific, cleavable antibodies
WO1996010089A1 (en) Modification of peptide and protein
JP2023529368A (ja) B7h3標的タンパク質及びその使用方法
AU2001278662A1 (en) NK cells activating receptors and their therapeutic and diagnostic uses
KR20240150525A (ko) 조건부 활성 폴리펩티드
JPH0889278A (ja) 遺伝子導入用修飾蛋白質及びその製法
JP2006517970A (ja) 癌免疫療法のための組成物及び方法
TW202320838A (zh) 誘導型細胞激素前藥及pd-1/pd-l1組合療法
KR20230160366A (ko) 암 치료를 위한 her2/4-1bb 이중특이적 융합 단백질
JP2023549761A5 (cg-RX-API-DMAC7.html)
EP2091972B1 (en) Multi-modal cancer therapy using viral hitch-hiking
JP2023548973A5 (cg-RX-API-DMAC7.html)
US20230406927A1 (en) Masked single-domain antibodies and methods thereof
US20260103541A1 (en) Paracrine Adenoviral Delivery of Biomolecules
US20230340499A1 (en) Constructs, compositions, cells and methods for increased recombinant protein expression by targeted integration and amplification
US11028132B1 (en) Half-life optimized linker composition
JP2023551068A5 (cg-RX-API-DMAC7.html)